Posted by Michael Wonder on 13 Nov 2023
In shocking reversal, CMS wants to allow Medicare Part D plan sponsors to substitute non-interchangeable biosimilars
10 November 2023 - On November 6, 2023, CMS announced a proposed Rule that would permit Medicare Part D plan sponsors to substitute non-interchangeable biosimilars in place of the biologic medicines now used to treat many chronic conditions such as rheumatoid arthritis, Crohn's disease and cancer.
The policy change represents a stark departure from the perspectives of the US medical community and patient advocacy organisations, a decade of state-level policy making, and CMS' recent assurances, warns the Alliance for Safe Biologic Medicines.
